Herein we evaluated 225Ac-DOTA-PRIT against GPA33, an antigen highly expressed in CRC, and HER2, an antigen with only 20% of the comparable antigen concentration, in terms of treatment efficacy. This evidence concerns the gene GPA33 and colorectal carcinoma.